Tony Coles was named chairman and Chief Executive Officer of Yumanity Therapeutics LLC in October of 2014. Yumanity Therapeutics is a biopharmaceutical company specializing in Alzheimer’s and Parkinson’s diseases. Just prior, Dr. Coles served as the chairman and chief executive officer of TRATE Enterprises LLC, a privately held company. Dr. Coles served as President, Chief Executive Officer, and Chairman of the Board of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from 2012–2013, having served as its President and Chief Executive Officer, and a member of its board of directors, from 2008–2012. Under his leadership, Onyx introduced two new innovative cancer medicines to patients and established the company’s international presence outside of the U.S.
Dr. Coles completed his cardiology and internal medicine training at Massachusetts General Hospital and was a research fellow at Harvard Medical School. He earned an M.D. degree from Duke University, a master’s degree in public health from Harvard University, and an undergraduate degree from Johns Hopkins University. Dr. Coles currently serves as a member of the board of directors of McKesson Corporation. He is vice chair of the board of trustees for Johns Hopkins University and is a member of the board of trustees for Johns Hopkins Medicine. Dr. Coles also serves as a director of the board of the U.S. Olympic and Paralympic Foundation and is a member of the Council of the Smithsonian’s National Museum of African American History and Culture.
Program Update | All of Us Marks One Year
(Play video to access audio description)
As the All of Us Research Program marks one year since its national launch, former Director Eric Dishman shares an update and previews what’s coming next for the program. This includes an update on the size and diversity of the health database that All of Us is building for researchers to speed up medical breakthroughs. Eric also announces the launch of the All of Us Research Program’s public Data Browser, which will be a valuable interactive tool for both participants and researchers. Stay tuned for more exciting updates from All of Us by following us on social media and signing up for our newsletter at JoinAllofUs.org .